Hanbing Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hanbing Zeng has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bin Zhang
Second Clinical Medical School,Zhejiang Chinese Medical University, Hangzhou, China
1 shared publicationBinbin Tang
Second Clinical Medical School,Zhejiang Chinese Medical University, Hangzhou, China
1 shared publicationChao Xu
Department of Orthopedics and Traumatology, Xinhua Hospital of Zhejiang Province, Hangzhou, China
1 shared publicationEnpin Guo
Second Clinical Medical School,Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication- Hongfeng Ruan
Institute of Orthopaedic and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), China
1 shared publication Lianguo Wu
Department of Orthopedics and Traumatology, Xinhua Hospital of Zhejiang Province, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5293-5309
Gubi Decoction Ameliorates Porous Cartilage Endplate in an Intervertebral Disc Degeneration Model Mouse Through Inhibition of NF-κB Activity and Pyroptosis
Background: Intervertebral disc (IVD) degeneration (IVDD) is highly prevalent among the elderly population and stands as a leading cause of low back pain. Our prior studies have highlighted the therapeutic potential of Gubi decoction (GBD) in alleviating knee osteoarthritis, however, but the specific mechanism of GBD in treating IVDD is not clear. Objective: To ascertain the clear mechanism of GBD for enhancing its therapeutic efficacy in treating lVDD, through comparison of its effects across different doses of GBD and clinical positive control drugs using a mouse IVDD model. Methods: In this study, 8-week-old male mice were treated with lumbar spine instability (LSI) surgery to construct IVDD model mice. From day 3 post-LSI surgery, mice in the loxoprofen sodium tablets (LST), GBD-L, GBD-M and GBD-H groups were gavage administration with LST (23.1 mg/kg) and GBD (6.1, 12.2 and 24.4 g/kg body weight, respectively) 5 times a week for 4 and 8 weeks separately. After 8 weeks of LSI modeling, the therapeutic efficacy on IVDD was evaluated through changes in lumbar spine function, histopathological morphology, extracellular matrix (ECM) metabolism, nucleus pulposus (NP) cell viability, and cartilage endplate (CEP) cell pyroptosis; at 4 weeks after modeling, the activation of NF-κB signaling was detected. Results: GBD can attenuate the progression of IVDD in mice, resulting in substantially increases disc height index (DHI) and NP matrix, reduced the degree of annulus fibrosus (AF) tear and the formation of cavity in CEP. In parallel, GBD significantly improved the matrix metabolism-related indexes of IVD at 8 weeks after modeling. Mechanically, GBD inhibited the expression of pyroptosis-related indicators NOD-like receptor thermal protein-domain associated protein 3 (NLRP3), cysteinyl aspartate specific-proteinase-1 (CASPASE1), gasdermin D (GSDMD), interleukin-1β (IL-1β) and interleukin-18 (IL-18) in CEP. Furthermore, GBD suppressed nuclear translocation of P65 protein, and decreased the amount of p-I-κB in CEP at 4 weeks after modeling. Conclusion: In summary, GBD can effectively inhibit the activation of NF-κB signaling and pyroptosis of ECP, relieve the porosity of ECP, and then delay the IVDD process. GBD may serve as a potential therapeutic agent for IVDD treatment.
- 1 April 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 5293-5309
Open AccessGubi Decoction Ameliorates Porous Cartilage Endplate in an Intervertebral Disc Degeneration Model Mouse Through Inhibition of NF-κB Activity and Pyroptosis
Background: Intervertebral disc (IVD) degeneration (IVDD) is highly prevalent among the elderly population and stands as a leading cause of low back pain. Our prior studies have highlighted the therapeutic potential of Gubi decoction (GBD) in alleviating knee osteoarthritis, however, but the specific mechanism of GBD in treating IVDD is not clear. Objective: To ascertain the clear mechanism of GBD for enhancing its therapeutic efficacy in treating lVDD, through comparison of its effects across different doses of GBD and clinical positive control drugs using a mouse IVDD model. Methods: In this study, 8-week-old male mice were treated with lumbar spine instability (LSI) surgery to construct IVDD model mice. From day 3 post-LSI surgery, mice in the loxoprofen sodium tablets (LST), GBD-L, GBD-M and GBD-H groups were gavage administration with LST (23.1 mg/kg) and GBD (6.1, 12.2 and 24.4 g/kg body weight, respectively) 5 times a week for 4 and 8 weeks separately. After 8 weeks of LSI modeling, the therapeutic efficacy on IVDD was evaluated through changes in lumbar spine function, histopathological morphology, extracellular matrix (ECM) metabolism, nucleus pulposus (NP) cell viability, and cartilage endplate (CEP) cell pyroptosis; at 4 weeks after modeling, the activation of NF-κB signaling was detected. Results: GBD can attenuate the progression of IVDD in mice, resulting in substantially increases disc height index (DHI) and NP matrix, reduced the degree of annulus fibrosus (AF) tear and the formation of cavity in CEP. In parallel, GBD significantly improved the matrix metabolism-related indexes of IVD at 8 weeks after modeling. Mechanically, GBD inhibited the expression of pyroptosis-related indicators NOD-like receptor thermal protein-domain associated protein 3 (NLRP3), cysteinyl aspartate specific-proteinase-1 (CASPASE1), gasdermin D (GSDMD), interleukin-1β (IL-1β) and interleukin-18 (IL-18) in CEP. Furthermore, GBD suppressed nuclear translocation of P65 protein, and decreased the amount of p-I-κB in CEP at 4 weeks after modeling. Conclusion: In summary, GBD can effectively inhibit the activation of NF-κB signaling and pyroptosis of ECP, relieve the porosity of ECP, and then delay the IVDD process. GBD may serve as a potential therapeutic agent for IVDD treatment.
- Open Access
- 13 June 2022
- Published by SAGE Publications in Geriatric Orthopaedic Surgery & Rehabilitation
- Vol. 13
Efficacy and Safety of Posterior Long-Segment Fixation Versus Posterior Short-Segment Fixation for Kummell Disease: A Meta-Analysis
Purpose: Posterior short-segment fixation (SSF) and long-segment fixation (LSF) are two methods for the treatment of Kummell disease, but the safety and effectiveness of these two surgical methods still lack adequate medical evidence. This study aimed to evaluate the two methods. Methods: Database searches for randomized controlled trials, case-control studies, and cohort studies of posterior SSF and posterior LSF in the treatment of Kummell disease were performed. After the document quality was evaluated with the Newcastle-Ottawa Quality Assessment Scale, a meta-analysis was carried out. Results: Meta-analysis revealed that the operation time and intraoperative blood loss in the LSF group were higher than those in the SSF group [MD = −18.17, 95% CI (−30.31, −6.03), z = 2.93, P = .003; MD = −82.07, 95% CI (−106.91, −57.24], z = 6.48, P < .00001). The postoperative last follow-up local kyphosis angle in the SSF group was greater than that in the LSF group (MD = 3.18, 95% CI [.56, 5.81], z = 2.38, P = .02), and there were no significant differences in perioperative complications, bone cement leakage rate, incidence of adverse events during follow-up, postoperative follow-up visual analog scale, postoperative Oswestry dysfunction index, and postoperative immediate local kyphosis angle between the two groups ( P > .05). Conclusion: SSF and LSF are effective and safe for the treatment of Kummell disease. SSF can reduce the operation time and intraoperative bleeding; LSF can better maintain the long-term stability of kyphosis. The methods should be evaluated by clinicians according to the individual situation of the patients.
- 13 June 2022
- Published by SAGE Publications in Geriatric Orthopaedic Surgery & Rehabilitation
- Vol. 13
Open AccessEfficacy and Safety of Posterior Long-Segment Fixation Versus Posterior Short-Segment Fixation for Kummell Disease: A Meta-Analysis
Purpose: Posterior short-segment fixation (SSF) and long-segment fixation (LSF) are two methods for the treatment of Kummell disease, but the safety and effectiveness of these two surgical methods still lack adequate medical evidence. This study aimed to evaluate the two methods. Methods: Database searches for randomized controlled trials, case-control studies, and cohort studies of posterior SSF and posterior LSF in the treatment of Kummell disease were performed. After the document quality was evaluated with the Newcastle-Ottawa Quality Assessment Scale, a meta-analysis was carried out. Results: Meta-analysis revealed that the operation time and intraoperative blood loss in the LSF group were higher than those in the SSF group [MD = −18.17, 95% CI (−30.31, −6.03), z = 2.93, P = .003; MD = −82.07, 95% CI (−106.91, −57.24], z = 6.48, P < .00001). The postoperative last follow-up local kyphosis angle in the SSF group was greater than that in the LSF group (MD = 3.18, 95% CI [.56, 5.81], z = 2.38, P = .02), and there were no significant differences in perioperative complications, bone cement leakage rate, incidence of adverse events during follow-up, postoperative follow-up visual analog scale, postoperative Oswestry dysfunction index, and postoperative immediate local kyphosis angle between the two groups ( P > .05). Conclusion: SSF and LSF are effective and safe for the treatment of Kummell disease. SSF can reduce the operation time and intraoperative bleeding; LSF can better maintain the long-term stability of kyphosis. The methods should be evaluated by clinicians according to the individual situation of the patients.